HealthDay News — For patients with breast cancer, moderate hypofractionation (MHF) shows an improved safety profile, cosmesis, and quality of life compared with conventional fractionation (CF), with ...

Adding trabectedin to treatment with doxorubicin improved progression-free and overall survival in patients with advanced leiomyosarcoma.

Investigators in Japan evaluated 1 week of oral naldemedine for treatment of opioid-induced constipation in cancer patients receiving palliative care in a real-world setting.

The hormone sensitivity of breast tissue makes it even more susceptible to damage from ionizing radiation from imaging ...

The effectiveness of the ONCORAL program in identifying drug-related problems in patients receiving oral anticancer therapy was determined in a prospective cohort study.

Study compared telehealth with in-person meeting as a modality for effective delivery of early palliative care.

These dedicated nursing roles can enhance care management of hospitalized patients undergoing radiotherapy and improve ...

In a retrospective study, investigators compared the risk of progression to end-stage kidney disease (ESKD) following partial nephrectomy and radical nephrectomy among patients with preoperative stage ...

Bintrafusp alfa has demonstrated activity in a phase 2 trial of patients with recurrent or metastatic cervical cancer.

A retrospective study explored the impact of preexisting cardiovascular disease on adverse events in patients with hematologic malignancies receiving BTK inhibitors.

Data suggest that neoadjuvant immune checkpoint inhibitor (ICI) therapy improves outcomes in patients with early-stage triple-negative breast cancer, but adjuvant ICI therapy does not.

Inotuzumab ozogamicin (InO) is an active antibody-drug conjugate that works by delivering the chemotherapeutic payload calicheamicin to cells expressing CD22. Studies demonstrate that InO elicits high ...